Autonomix Medical, Inc.
AI Executive Summary
AI-powered analysis of 10-Q filing content
Autonomix Medical shows significant financial deterioration with 9-month net losses increasing 71% to $14.0M versus $8.2M prior year. R&D expenses surged 79% indicating heavy pre-revenue investment phase, while cash position of $9.9M provides limited runway given current burn rate exceeding $14M annually.
Red Flags Detected (5)
Net loss increased 71% year-over-year for nine months ($14.0M vs $8.2M)
Operating expenses jumped 71% to $14.3M with no revenue generation
Cash burn rate of ~$14M annually with only $9.9M cash remaining
2 more red flags detected
Key Takeaways
Company is in intensive R&D phase with 79% increase in development spending
Current cash runway appears limited at less than 9 months based on burn rate
2 more takeaways
Filing Overview
What This Means
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.